Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.
Recent Advances for CAR T- Cell Therapy in R/R Multiple Myeloma
March 15th 2024Dr Dhakal provided an overview of the clinical hallmarks and risk stratification for R/R MM, as well as the current standard of care treatment options. He explored the role of CAR T-cell therapy in this setting, including an overview of the CAR-T process and criteria for identifying suitable patients.
Read More
Expert Insights into Recent Updates for the Management of Lower-Risk MDS
December 13th 2023Guillermo Garcia-Manero, MD, discusses recent advances presented at ASH 2023 in the treatment of myelodysplastic syndrome, highlighting both safety and efficacy of regimens in the frontline and second line setting.
Read More
The Evolving Treatment Landscape in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
November 28th 2023Siamak Daneshmand, MD, provides an overview of BCG-unresponsive non-muscle invasive bladder cancer and the currently available treatment options; Dr Daneshmand explains that new intravesical therapies like the TAR-200 device show promise but still require vigilant monitoring to avoid delaying cystectomy, which remains the best chance for long-term management.
Read More
Understanding Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC)
January 17th 2023Lori Wirth, MD, provides an overview of radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC), the standard-of-care treatment options, and the importance of testing for molecular alterations in patients with RAI-R-DTC.
Read More
Metastatic Renal Cell Carcinoma: Updates to CheckMate 9ER and COSMIC-313 Trial Data
December 20th 2022Rana McKay, MD discusses emerging data in the metastatic renal cell carcinoma treatment landscape, reviewing the current standard of care and then delving into recent data updates from the CheckMate 9ER and COSMIC-313 trials.
Read More
Treating Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) with Lenvatinib
November 16th 2022Lori Wirth, MD, reviews real-world and clinical trial data on treatment of advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC) with lenvatinib, and her personal experience with lenvatinib in clinical practice.
Read More
Potential Role of Elacestrant for the Treatment of Metastatic ER+/HER2- Breast Cancer
October 31st 2022Dr Aditya Bardia reviews the potential role of elacestrant for the treatment of metastatic ER+/HER2- breast cancer, starting with an overview of the current landscape and focusing specifically on key efficacy data from the EMERALD Trial.
Read More
Metastatic Castration-Resistant Prostate Cancer: Updates to VISION Trial Data
April 14th 2022Scott Tagawa, MD, MS, FACP, comments on treatment and management strategies in metastatic castration-resistant prostate cancer (CRPC), and reviews recent data on the VISION trial of Lu 177 vipivotide tetraxetan.
Read More